European Patent Paves Way for BioNxt’s Multiple Sclerosis Innovation
Published on 11/09/2025 at 04:19 | Redaktion boerse-global.de
A recent decision by the European Patent Office has positioned BioNxt Solutions for a potential breakthrough in multiple sclerosis treatment. While major pharmaceutical companies continue focusing on conventional tablets, this biotechnology firm is pioneering a novel drug delivery approach that could transform patient care standards across the continent.
On November 4, the European Patent Office indicated its intention to grant protection for BioNxt’s sublingual cladribine film formulation. This patent coverage would extend across 54 European and Eurasian markets encompassing nearly one billion people—representing a substantial corporate milestone.
The protected formulation, designated BNT23001, consists of a dissolvable thin-film strip administered under the tongue. This delivery method eliminates the need for Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
